Ionis Pharmaceuticals management to meet with Oppenheimer
PremiumThe FlyIonis Pharmaceuticals management to meet with Oppenheimer
14d ago
JPMorgan healthcare analysts hold an analyst/industry conference call
Premium
The Fly
JPMorgan healthcare analysts hold an analyst/industry conference call
20d ago
Truist biotech analysts hold an analyst/industry conference call
Premium
The Fly
Truist biotech analysts hold an analyst/industry conference call
22d ago
Ionis downgraded to Market Perform from Outperform at BMO Capital
PremiumThe FlyIonis downgraded to Market Perform from Outperform at BMO Capital
2M ago
Ionis Pharmaceuticals says ‘on track to achieve 2024 financial guidance’
Premium
The Fly
Ionis Pharmaceuticals says ‘on track to achieve 2024 financial guidance’
2M ago
Ionis Pharmaceuticals reports Q2 EPS (45c), consensus (92c)
Premium
The Fly
Ionis Pharmaceuticals reports Q2 EPS (45c), consensus (92c)
2M ago
Ionis Pharmaceuticals price target raised to $68 from $67 at BofA
PremiumThe FlyIonis Pharmaceuticals price target raised to $68 from $67 at BofA
2M ago
Ionis Pharma’s ION582 shows positive Phase 1/2 results in Angelman syndrome
Premium
The Fly
Ionis Pharma’s ION582 shows positive Phase 1/2 results in Angelman syndrome
2M ago
Ionis Pharmaceuticals completes enrollment in trial of zilganers in AxD
Premium
The Fly
Ionis Pharmaceuticals completes enrollment in trial of zilganers in AxD
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100